Fosinopril tablet formulations

Abstract: Shelf stable tablets containing fosinopril sodium are prepared by employing either sodium stearyl fumarate or hydrogenated vegetable oil as the lubricant. The tablets can contain conventional excipients such as fillers, binders, and disintegrants as well as an optional diuretic.

Description: The sodium salt of fosinopril, (4S)-4-cyclohexyl-1-[[[(RS)-1-hydroxy-2-methylpropoxy](4-phenylbutyl)phosphinyl]acetyl]-L-proline, propionate (ester) sodium salt, is currently undergoing clinical evaluation as an antihypertensive agent. Fosinopril, its ability to inhibit the angiotensin converting enzyme and thus lower blood pressure in humans, and formulations of fosinopril including combinations with various diuretics are described in United States Patents US-A-4,337,201 and US-A-4,384,123. The present invention is concerned with the use of particular lubricants in tablets containing fosinopril sodium. European Patent Application EP-A-288907 discloses an Angiotensin Converting Enzyme Inhibitor tablet formulation suitable for oral administration comprising gelatin as a binder, corn starch as a disintegrant, microcrystalline cellulose or lactose as a filler and magnesium stearate as a lubricant. Lexikon der Hilfstoffe fuer Pharmazie, Kosmetik und angegrenzde Gebiete, H.P. Fiedler, Band II (L-Z), 1989, Editio Cantor Aulendorf, page 858, "Natriumstearylfumarat" indicates that sodium stearyl fumarate is an alternative to magnesium stearate. This invention is directed to the discovery that the shelf life and stability of fosinopril sodium formulated as tablets is increased when the lubricant employed is sodium stearyl fumarate or hydrogenated vegetable oil as compared to tablets employing magnesium stearate as the lubricant. In addition to the fosinopril sodium, the tablet formulation can also include a diuretic, preferably chlorthalidone, a filler, a disintegrant, a binder, a lubricant, and other commonly employed pharmaceutically acceptable agents. The tablet can include a color agent or the tablets can be color film coated. The tablets can be prepared in a variety of shapes and can be scored for the convenience of the user. More specifically the invention provides a stable tablet comprising, on a weight percentage basis, from 1% to 25% fosinopril sodium, from 0% to 25% of a diuretic, from 30% to 90% of a filler, from 2% to 10% of a disintegrant, from 1% to 5% of a binder, or from 5% to 15% of a single agent which is both binder and disintegrant, and from 0.3% to 4% of a lubricant selected from sodium stearyl fumarate and hydrogenated vegetable oil. Fosinopril sodium having the chemical formula is an angiotensin converting enzyme inhibitor currently being clinically evaluated as an anti-hypertensive agent. Fosinopril sodium bulk material has a relatively low bulk density, exhibits poor flow characteristics, and adheres to metal surfaces during tableting. Previously, fosinopril sodium was tableted by a wet granulation process in which the tablet binder material was added to a solvent to form a solution of about 20% on a weight to weight basis. The fosinopril sodium and a portion of the tablet filler and disintegrant were then added. The mix was granulated and dried to less than 1% by weight of volatiles. The remainder of the tablet excipients were added and the final blend was obtained by lubrication with magnesium stearate. It was found that tablets produced from this blend were moisture sensitive and only marginally stable. In order to have a useful shelf life these tablets required the use of a protective package. This invention is based on the discovery that by employing sodium stearyl fumarate or hydrogenated vegetable oil as the lubricant during the tableting of fosinopril sodium (instead of magnesium stearate), tablets having improved stability are obtained. The tablets thus prepared are significantly less moisture sensitive and have a useful shelf life without the need for protective packaging. Sodium stearyl fumarate is the preferred lubricant since hydrogenated vegetable oil can cause processing problems of sticking to the punch tips during long tableting runs. As discussed in United States Patents US-A-4,337,201 and US-A-4,384,123, various diuretics can be combined with fosinopril sodium for the treatment of hypertension. Suitable diuretics include chlorthalidone, the thiazide diuretics such as chlorothiazide, hydrochlorothiazide, flumethiazide, bendroflumethiazide, etc., ethacrynic acid, ticrynafen, furosemide, musolimine, bumetanide, triameterene, amiloride, spironolactone, and salts thereof with chlorthalidone and hydrochlorothiazide being preferred. Tablets prepared according to this invention generally contain from 5 mg. to 50 mg. of fosinopril sodium as the sole active agent or from 10 mg. to 75 mg. of a combination of fosinopril sodium and diuretic in a ratio of from 1:5 to 5:1 on a weight basis. As discussed above, in addition to the actives, fosinopril sodium and the optional diuretic, and the lubricant, tablets prepared according to this invention will include excipients such as a filler, a disintegrant, and a binder. The preferred filler is lactose or lactose and microcrystalline cellulose. The preferred disintegrants are selected from sodium carboxymethyl starch, cross linked sodium carboxymethyl starch, crospovidone, i.e., 1-ethenyl-2-pyrrolidinone homopolymer, cross linked sodium carboxymethylcellulose (AcDiSol® or Croscarmellose Sodium®), sodium starch glycolate, and mixtures thereof. The preferred binders are selected from povidone, i.e., 2-pyrrolidinone, 1-ethenyl-, homopolymer, hydroxypropyl cellulose, and mixtures thereof. Alternatively, a single agent such as pregelatinzed starch can be employed as both disintegrant and binder. Other ingredients commonly employed in tableting pharmaceutical products can also be included such as coloring agents. On a weight percentage basis, the above ingredients will preferably be present in the final tablets as follows: The fosinopril sodium tablets of this invention can be prepared by conventional tablet forming techniques such as, for example, wet granulation and dry granulation. In the wet granulation process, the active ingredient or ingredients are mixed with portions of the filler and disintegrant. This blend is then wet granulated with a solution of the binder in a solvent. The solution will preferably be from 5% to 20% by weight of solvent and the preferred solvents include ethanol, isopropanol, and water. The resultant wet granulation is then dried and milled. The dried granulation is then mixed with the balance of the filler and disintegrant. The resulting blend is mixed with sodium stearyl fumarate, which is preferred, or hydrogenated vegetable oil to produce the final mix which is then compressed into tablets. In the dry granulation process, the active ingredient or ingredients and the filler, disintegrant and binder are blended in a mixer (planetary or high shear) for several minutes. The blend is then milled and mixed with sodium stearyl fumarate, which is preferred, or hydrogenated vegetable oil to produce the final mix which is then compressed into tablets. The wet granulation process employing water as the solvent and the dry granulation process have the added advantage of avoiding the use of an organic solvent. This results in a cost savings as well as a safer process needing fewer environmental controls. Example 1 Tablets were prepared containing: 100,000 tablets of the above formulation were prepared as follows. A blend was prepared of fosinopril sodium (4000 g), chlorthalidone (1500 g), lactose (17,900 g), and crospovidone (700 g) in a suitable mixer such as planetary mixer or high shear mixer for 5 to 10 minutes. Povidone (900 g) was dissolved in water (7 liters) and the above blend was wet granulated with the entire povidone solution. The wet granulation was dried at 45 - 70° C. in a suitable dryer such as a tray drying oven or a fluid bed dryer until the volatile content of the wet granulation was less than 3% by weight. The dried granulation was passed through a hammer mill fitted with 0.03 - 0.07 inch screen operating at medium to fast speed, knives forward. The screened granulation was then mixed with lactose (13,900 g) and crospovidone (700 g) in the mixer (planetary or high shear) for 5 to 10 minutes. Sodium stearyl fumarate (400 g) was then added to the above blend and mixing was continued for 1 to 3 minutes. The final blend was then compressed into 400 mg tablets using a rotary tablet press. Examples 2 to 5 Following the procedure of Example 1, the following tablets were obtained. Examples 6 to 9 Following the procedure of Examples 1 to 5, the following tablets were obtained. Examples 10 and 11 The following tablets were prepared by a modification of the procedures of Examples 1 to 9. In the preparation of the tablets of Examples 10 and 11, a portion of the pregelatinized starch was added before the wet granulation step and the remainder was added to the dried granulation. Example 12 Tablets were prepared containing the following: 200,000 tablets of the above formulation were prepared as follows. Fosinopril sodium (1,000 g), lactose (16,500 g), Avicel (1,000 g) and crospovidone (700 g) were mixed in a suitable mixer (planetary or high shear) for 5 to 10 minutes. Povidone (800 g) was dissolved in denatured alcohol (4 liters) and blended with the above mixture forming a wet granulate. This wet granulate was dried at 45 - 70° C. in suitable dryer such as a tray drying oven or a fluid bed dryer until the volatile content of the wet granulation was less than 3% by weight. The dried granulation was passed through a hammer mill fitted with a 0.76 mm - 1.75 mm (0.03 - 0.07 inch) screen operating at medium to fast speed, knives forward. The screened granulation was mixed with lactose (12,100 g), Avicel® (7,000 g) and crospovidone (700 g) in a suitable mixer (planetary or high shear) for 5 to 10 minutes. Sodium stearyl fumarate was added to the above blend and mixed for 1 to 3 minutes in the same mixer. This final blend was then compressed into 200 mg tablets using a rotary tablet press. Examples 13 and 14 Following the procedure of Example 12, the following tablets were obtained. Example 15 Tablets were prepared containing the following: 200,000 tablets of the above formulation were prepared as follows. Fosinopril sodium (1,000 g), lactose (28,600 g), Avicel® (8,000 g), crospovidone (1400 g) and povidone (800 g) were mixed in a suitable mixer (planetary or high shear) for 5 to 10 minutes. The blend was then passed through a hammer mill equipped with a 0.04 - 0.08 inch size round hole screen operating at medium speed, knives forward. Sodium stearyl fumarate (200 g) was added to the above blend and mixed for 1 to 3 minutes in the same mixer. This final blend was then compressed into 200 mg. tablets using a rotary tablet press. Following the procedures of Examples 1 to 5 and 12 to 15, similar tablets were prepared substituting hydrogenated vegetable oil for the sodium stearyl fumarate. Example 16 Following the procedure of Example 12 fosinopril sodium tablets were prepared utilizing sodium stearyl fumarate, hydrogenated vegetable oil, and magnesium fumarate as the lubricant. The initial amount of fosinopril sodium was measured and similar measurements were made after 10 days and 25 days storage under varying conditions.

Claims: Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE A stable tablet comprising, on a weight percentage basis, from 1% to 25% fosinopril sodium, from 0% to 25% of a diuretic, from 30% to 90% of a filler, from 2% to 10% of a disintegrant, from 1% to 5% of a binder, or from 5% to 15 %of a single agent which is both binder and disintegrant, and from 0.3% to 4% of a lubricant selected from sodium stearyl fumarate and hydrogenated vegetable oil. The tablet of Claim 1 wherein said lubricant is sodium stearyl fumarate. The tablet of Claim 2 wherein said filler is lactose or a blend of lactose and microcrystalline cellulose, said disintegrant is selected from sodium carboxymethyl starch, cross linked sodium carboxymethyl starch, crospovidone, cross linked sodium carboxymethylcellulose, sodium starch glycolate, and mixtures thereof, said binder is selected from povidone, hydroxypropyl cellulose, and mixtures thereof, and said single agent which is both binder and disintegrant is pregelatinized starch. The tablet of Claim 3 containing from 1% to 25% by weight of chlorthalidone. The tablet of Claim 4 wherein said filler is lactose, said disintegrant is crospovidone, and said binder is povidone. The tablet of Claim 5 containing on a weight percentage basis 10% fosinopril sodium, 3.75% chlorthalidone, 79.5% lactose, 2.25% povidone, 3.5% crospovidone, and 1% sodium stearyl fumarate. The tablet of Claim 5 containing, on a weight percentage basis, 6.67% fosinopril sodium, 5% chlorthalidone, 81.58% lactose, 2.25% povidine, 3.5% crospovidone, and 1% sodium stearyl fumarate. The tablet of Claim 5 containing, on a weight percentage basis, 5% fosinopril sodium, 7.5% chlorthalidone, 80.5% lactose, 2.25% povidone, 3.75% crospovidone, and 1% sodium stearyl fumarate. The tablet of Claim 5 containing, on a weight percentage basis, 5% fosinopril sodium, 25% chlorthalidone, 62.5% lactose, 3.0% povidone, 3.5% crospovidone, and 1% sodium stearyl fumarate. The tablet of Claim 5 containing, on a weight percentage basis, 5% fosinopril sodium, 5% chlorthalidone, 82.5% lactose, 3% povidone, 3.5% crospovidone, and 1% sodium stearyl fumarate. The tablet of Claim 3 wherein the only active ingredient is fosinopril sodium. The tablet of Claim 11 wherein said filler is a mixture of lactose and microcrystalline cellulose, said disintegrant is crospovidone, and said binder is povidone. The tablet of Claim 12 containing, on a weight percentage basis, 2.5% fosinopril sodium, 69.75% lactose, 20% microcrystalline cellulose, 3.5% crospovidone, 2.25% povidone, and 2% sodium stearyl fumarate. The tablet of Claim 12 containing, on a weight percentage basis, 5% fosinopril sodium, 67.25% lactose, 20% microcrystalline cellulose, 3.5% crospovidone, 2.25% povidone, and 2% sodium stearyl fumarate. The tablet of Claim 12 containing, on a weight percentage basis, 10% fosinopril sodium, 62.25% lactose, 20% microcrystalline cellulose, 3.5% crospovidone, 2.25% povidone, and 2% sodium stearyl fumarate. The tablet of Claim 12 containing, on a weight percentage basis, 2.5% fosinopril sodium, 71.5% lactose, 20% microcrystalline cellulose, 3.5% crospovidone, 2% povidone, and 0.5% sodium stearyl fumarate. The tablet of Claim 3 containing from 1% to 25% by weight of hydrochlorothiazide. The tablet of Claim 17 wherein said filler is lactose or a blend of lactose and microcrystalline cellulose, said disintegrant is cross linked sodium carboxymethylcellulose or sodium starch glycolate, said binder is povidone, and said single agent which is both binder and disintegrant is pregelatinized starch. The tablet of Claim 18 containing, on a weight percentage basis, 6.6% fosinopril sodium, 4.2% hydrochlorothiazide, 79.2% lactose, 2.0% povidone, 5.0% cross linked sodium carboxymethylcellulose, and 3.0% sodium stearyl fumarate. The tablet of Claim 18 containing, on a weight percentage basis, 5.0% fosinopril sodium, 6.25% hydrochlorothiazide, 78.75% lactose, 2.0% povidone, 5.0% cross linked sodium carboxymethylcellulose, and 3.0% sodium stearyl fumarate. The tablet of Claim 18 containing, on a weight percentage basis, 10.0% fosinopril sodium, 6.25% hydrochlorothiazide, 56.25% lactose, 20.0% microcrystalline cellulose, 2.0% povidone, 3.5% sodium starch glycolate, and 2.0% sodium stearyl fumarate. The tablet of Claim 18 containing, on a weight percentage basis, 5.0% fosinopril sodium, 6.25% hydrochlorothiazide, 61.75% lactose, 20.0% microcrystalline cellulose, 2.0% povidone, 3.5% sodium starch glycolate, and 1.5% sodium stearyl fumarate. The tablet of Claim 18 containing, on a weight percentage basis, 10.0% fosinopril sodium, 6.25% hydrochlorothiazide, 53.75% lactose, 20.0% microcrystalline cellulose, 8.0% pregelatinized starch, and 2.0% sodium stearyl fumarate. The tablet of Claim 18 containing, on a weight percentage basis, 5.0% fosinopril sodium, 6.25% hydrochlorothiazide, 59.25% lactose, 20.0% microcrystalline cellulose, 8.0% pregelatinized starch, and 1.5% sodium stearyl fumarate. A method of making the tablet of any preceding claim comprising formulating a composition capable of making a tablet having the indicated ingredients in the indicated proportions and forming a tablet from the composition. Claims for the following Contracting States : ES, GR A method of making a tablet with improved storage stability comprising, on a weight percentage basis, from 1% to 25% fosinopril sodium, from 0% to 25% of a diuretic, from 30% to 90% of a filler, from 2% to 10% of a disintegrant, and from 1% to 5% of a binder, or from 5% to 15% of a single agent which is both binder and disintegrant, said method comprising: (a) providing said ingredients; (b) including in said ingredients from 0.3% to 4% of a lubricant selected from sodium stearyl fumarate and hydrogenated vegetable oil; and (c) forming a tablet containing said ingredients and said lubricant. The method of claim 1 wherein said lubricant is sodium stearyl fumarate. The method of claim 2 wherein said filler is lactose or a blend of lactose and microcrystalline cellulose, said disintegrant is selected from sodium carboxymethyl starch, cross linked sodium carboxymethyl starch, crospovidone, cross linked sodium carboxymethylcellulose, sodium starch glycolate, and mixtures thereof, said binder is selected from povidone, hydroxypropyl cellulose, and mixtures thereof, and said single agent which is both binder and disintegrant is pregelatinized starch. The method of claim 3 wherein said tablet contains from 1% to 25% by weight of chlorthalidone. The method of claim 4 wherein said filler is lactose, said disintegrant is crospovidone, and said binder is povidone. The method of claim 5 wherein said tablet contains, on a weight percentage basis, 10% fosinopril sodium, 3.75% chlorthalidone, 79.5% lactose, 2.25% povidone, 3.5% crospovidone, and 1% sodium stearyl fumarate. The method of claim 5 wherein said tablet contains, on a weight percentage basis, 6.67% fosinopril sodium, 5% chlorthalidone, 81.58% lactose, 2.25% povidone, 3.5% crospovidone, and 1% sodium stearyl fumarate. The method of claim 5 wherein said tablet contains, on a weight percentage basis, 5% fosinopril sodium, 7.5% chlorthalidone, 80.5% lactose, 2.25% povidone, 3.75% crospovidone, and 1% sodium stearyl fumarate. The method of claim 5 wherein said tablet comprises, on a weight percentage basis, 5% fosinopril sodium, 25% chlorthalidone, 62.5% lactose, 3.0% povidone, 3.5% crospovidone, and 1% sodium stearyl fumarate. The method of claim 5 wherein said tablet comprises, on a weight percentage basis, 5% fosinopril sodium, 5% chlorthalidone, 82.5% lactose, 3% povidone, 3.5% crospovidone, and 1% sodium stearyl fumarate. The method of claim 3 wherein the only active ingredient is fosinopril sodium. The method of claim 11 wherein said filler is a mixture of lactose and microcrystalline cellulose, said disintegrant is crospovidone, and said binder is povidone. The method of claim 12 wherein said tablet contains, on a weight percentage basis, 2.5% fosinopril sodium, 69.7% lactose, 20% microcrystalline cellulose, 3.5% crospovidone, 2.25% povidone, and 2% sodium stearyl fumarate. The method of claim 12 wherein said tablet contains, on a weight percentage basis, 5% fosinopril sodium, 67.25% lactose, 20% microcrystalline cellulose, 3.5% crospovidone, 2.25% povidone, and 2% sodium stearyl fumarate. The method of claim 12 wherein said tablet contains, on a weight percentage basis, 10% fosinopril sodium, 62.25% lactose, 20% microcrystalline cellulose, 3.5% crospovidone, 2.25% povidone, and 2% sodium stearyl fumarate. The method of claim 12 wherein said tablet contains, on a weight percentage basis, 2.5% fosinopril sodium, 71.5% lactose, 20% microcrystalline cellulose, 3.5% crospovidone, 2% povidone, and 0.5% sodium stearyl fumarate. The method of claim 3 wherein said tablet contains from 1% to 25% by weight of hydrochlorothiazide. The method of claim 17 wherein said filler is lactose or a blend of lactose and microcrystalline cellulose, said disintegrant is cross linked sodium carboxymethylcellulose or sodium starch glycolate, said binder is povidone, and said single agent which is both binder and disintegrant is pregelatinized starch. The method of claim 18 wherein said tablet contains, on a weight percentage basis, 6.6% fosinopril sodium, 4.2% hydrochlorothiazide, 79.2% lactose, 2.0% povidone, 5.0% cross linked sodium carboxymethylcellulose, and 3.0% sodium stearyl fumarate. The method of claim 18 wherein said tablet contains, on a weight percentage basis, 5.0% fosinopril sodium, 6.25% hydrochlorothiazide, 78.75% lactose, 2.0% povidone, 5.0% cross linked sodium carboxymethylcellulose, and 3.0% sodium stearyl fumarate. The method of claim 18 wherein said tablet contains, on a weight percentage basis, 10.0% fosinopril sodium, 6.25% hydrochlorothiazide, 56.25% lactose, 20.0% microcrystalline cellulose, 2.0% povidone, 3.5% sodium starch glycolate, and 2.0% sodium stearyl fumarate. The method of claim 18 wherein said tablet contains, on a weight percentage basis, 5.0% fosinopril sodium, 6.25% hydrochlorothiazide, 61.75% lactose, 20.0% microcrystalline cellulose, 2.0% povidone, 3.5% sodium starch glycolate, and 1.5% sodium stearyl fumarate. The method of claim 18 wherein said tablet contains, on a weight percentage basis, 10.0% fosinopril sodium, 6.25% hydrochlorothiazide, 53.75% lactose, 20.0% microcrystalline cellulose, 8.0% pregelatinized starch, and 2.0% sodium stearyl fumarate. The method of claim 18 wherein said tablet contains, on a weight percentage basis, 5.0% fosinopril sodium, 6.25% hydrochlorothiazide, 59.25% lactose, 20.0% microcrystalline cellulose, 8.0% pregelatinized starch, and 1.5% sodium stearyl fumarate. The method of any preceding claim which comprises wet granulation or dry granulation.

Inventors: GRYZIEWICZ LEWIS J, JAIN NEMICHAND B, JERZEWSKI ROBERT L, THAKUR AJIT B, WONG THOMAS M, GRYZIEWICZ, LEWIS J., JAIN, NEMICHAND B., JERZEWSKI, ROBERT L., THAKUR, AJIT B., WONG, THOMAS M.
Applicants: SQUIBB & SONS INC, E.R. SQUIBB & SONS, INC.
Application year: 1990
Main classification: A61K31
IPC codes: A61P43, A61P9, A61K47, A61K31, A61K9